Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
Trial details
- Registry ID
- NCT03719690
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690 | KURA | Phase 2 | Completed | 2023-05-02Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |